AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 15345733
Drug: 0.25 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.25 mg/day micronized 17beta-estradiol (E2)
Trial: 15345733
Drug: 1 mg/day
RxNorm normalized name: Lyllana 0.1 MG/Day Transdermal Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg/day micronized 17beta-estradiol (E2)
Trial: 15345733
Drug: 0.5 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg/day micronized 17beta-estradiol (E2)
Trial: 10209728
Drug: Oral brovincamine
RxNorm normalized name: vincamine
DrugBank: Vincamine (DB13374)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral brovincamine (20 mg three times daily)
Trial: 722768
Drug: Ratings administered
RxNorm normalized name: Aratinga erythrogenys feather extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ratings administered immediately before or after the final examination
Trial: 19873916
Drug: Electroacupuncture (Baihui
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electroacupuncture (Baihui (GV 20) and Taiyang (EXHN 5), once daily)
Trial: 19873916
Drug: Modified Electric
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified Electric Convulsive Therapy (MECT, treatment once every 2 or 3 days for 14 to 21 days)
Trial: 18214053
Drug: Ondansetron conventional
RxNorm normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ondansetron conventional tablet (OT) 8 mg twice daily for 3 days
Trial: 18214053
Drug: Ondansetron orally
RxNorm normalized name: Ondansetron Orally Disintegrating Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ondansetron orally disintegrating tablet (ODT) 8 mg twice daily for 3 days
Trial: 15126539
Drug: Dutasteride 5.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dutasteride 5.0 mg
Trial: 11414666
Drug: N-acetylcysteine (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N-acetylcysteine (6 g daily for three days)
Trial: 9215320
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg DHEA daily for 2 weeks
Trial: 1917031
Drug: Cefaclor (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefaclor (250 mg t.i.d. for seven days)
Trial: 1917031
Drug: Amoxycillin (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxycillin (250 mg t.i.d. for seven days)
Trial: 7042501
Drug: Cefamandole prophylactic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefamandole prophylactic therapy
Trial: 26660491
Drug: 1.5% 3-butenyl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5% 3-butenyl 5-aminolevulinate gel (ALA-bu)
Trial: 15801938
Drug: Gemfibrozil 600
RxNorm normalized name: gemfibrozil 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemfibrozil 600 mg twice daily for 8 days
Trial: 10233489
Drug: Hybrid laser
RxNorm normalized name: Amaranthus hybridus pollen
DrugBank: Amaranthus hybridus pollen (DB15503)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hybrid laser treatment (30 W KTP and 60 W Nd:YAG)
Trial: 31739840
Drug: Montelukast sodium
RxNorm normalized name: Montelukast Sodium
DrugBank: Montelukast (DB00471)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Montelukast sodium chewable tablets combined with inhaled budesonide
Trial: 31739840
Drug: Single-drug group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-drug group (either montelukast sodium or budesonide)
Trial: 22076751
Drug: Atorvastatin (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin (40 mg/day for 14 days)
Trial: 11169254
Drug: HLA-G*0105N allele
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HLA-G*0105N allele
Trial: 15090794
Drug: HLA-G*010108 allele
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HLA-G*010108 allele
Trial: 15090794
Drug: HLA-G*010108/010401 genotype
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HLA-G*010108/010401 genotype
Trial: 15090794
Drug: HLA-G*010101/010108 genotype
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HLA-G*010101/010108 genotype
Trial: 3154674
Drug: Nisoldipine 10
RxNorm normalized name: nisoldipine 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nisoldipine 10 mg once a day
Trial: 26240230
Drug: thyroid hormone
RxNorm normalized name: Thyroid hormone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: thyroid hormone withdrawal (THW)
Trial: 18082498
Drug: Class IC
RxNorm normalized name: Antiarrhythmics, class Ic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Class IC antiarrhythmic drugs (AADs)
Trial: 14572748
Drug: Strontium(89) Chloride
RxNorm normalized name: strontium chloride
DrugBank: Strontium chloride (DB13987)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Strontium(89) Chloride (150MBq, single intravenous injection)
Trial: 19062012
Drug: Low-dose oral
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose oral contraceptive alone
Trial: 19062012
Drug: Low-dose oral
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose oral contraceptive combined with a GnRH analog
Trial: 11722711
Drug: Topical clobetasol
RxNorm normalized name: clobetasol Topical Foam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical clobetasol propionate ointment (0.05%) applied three times a day
Trial: 11722711
Drug: Clobetasol propionate
RxNorm normalized name: Clobetasol Propionate
DrugBank: Clobetasol propionate (DB01013)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Clobetasol propionate in an oral analgesic base (Orabase‐B) (1:1) applied two times a day
Trial: 8989238
Drug: GH therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GH therapy (12.5 micrograms/kg per day)
Trial: 8480572
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no preprocedural heparin)
Trial: 2953219
Drug: Nafazatrom 800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nafazatrom 800 mg four times daily for 1 week
Trial: 2953219
Drug: Nafazatrom 1600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nafazatrom 1600 mg four times daily for 1 week
Trial: 2953219
Drug: Nafazatrom treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nafazatrom treatment
Trial: 29769450
Drug: HSPPC‐96 vaccination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HSPPC‐96 vaccination in combination with standard treatment after surgical resection
Trial: 18391619
Drug: New prognostic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New prognostic classification based on residual disease after neoadjuvant chemotherapy
Trial: 14526714
Drug: CHM extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CHM extract capsule (containing 18 herbs), given daily for 8 weeks
Trial: 14526714
Drug: Placebo, given
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, given daily for 8 weeks
Trial: 14526714
Drug: CHM extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CHM extract capsule
Trial: 8879380
Drug: Oral ifosfamide
RxNorm normalized name: Ifosfamide
DrugBank: Ifosfamide (DB01181)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral ifosfamide (OSI) at a dose of 1 g/day for 14 days every 4 weeks
Trial: 8879380
Drug: Intravenous ifosfamide
RxNorm normalized name: Ifosfamide
DrugBank: Ifosfamide (DB01181)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous ifosfamide (IVI) at a dose of 1.6 g/m2/day for 5 days every 4 weeks
Trial: 8879380
Drug: Oral ifosfamide
RxNorm normalized name: Ifosfamide
DrugBank: Ifosfamide (DB01181)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral ifosfamide (OSI)
Trial: 8879380
Drug: Intravenous ifosfamide
RxNorm normalized name: Ifosfamide
DrugBank: Ifosfamide (DB01181)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous ifosfamide (IVI)
Trial: 1848054
Drug: Low molecular
RxNorm normalized name: Low molecular weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low molecular weight heparin (Enoxaparin), 30 mg subcutaneously twice daily for 14 days or until discharge.
Trial: 1848054
Drug: Standard calcium
RxNorm normalized name: Stangard
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Standard calcium heparin, 7500 units subcutaneously twice daily for 14 days or until discharge.
Trial: 31022366
Drug: Combination instruments
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination instruments (hearing aids with a built-in sound generator)
Trial: 29651778
Drug: Telephone follow-up
RxNorm normalized name: Q-Up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telephone follow-up administered by specialist nurses
Trial: 26849442
Drug: Direct observation
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Direct observation of treatment (DOT) provided by a family member
Trial: 26849442
Drug: Direct observation
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Direct observation of treatment (DOT) provided by a non-family member (usual-practice)
Trial: 20100767
Drug: Treatment of
RxNorm normalized name: DRUGS FOR TREATMENT OF LEPRA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment of both clinical seizures and subclinical seizure patterns (group A)
Trial: 20100767
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (blinding of aEEG registration and treatment of clinical seizures only, group B)
Trial: 20100767
Drug: Treatment group
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment group (group A)
Trial: 2899840
Drug: Diltiazem (240
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diltiazem (240 mg per day, n = 1234)
Trial: 29473382
Drug: Solifenacin Succinate
RxNorm normalized name: Solifenacin Succinate
DrugBank: Solifenacin (DB01591)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Solifenacin Succinate (SS), 5 mg once a day for 12 weeks
Trial: 29473382
Drug: Complementary and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Complementary and Alternative Medicine (CAM), 930 mg twice daily for 12 weeks
Trial: 25152207
Drug: Telbivudine plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telbivudine plus PegIFN alpha‐2a (combination therapy)
Trial: 25152207
Drug: Telbivudine monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telbivudine monotherapy
Trial: 25152207
Drug: PegIFN alpha‐2a
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PegIFN alpha‐2a monotherapy
Trial: 21211688
Drug: Absence of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Absence of beta-blockers
Trial: 18241759
Drug: Endovascular treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endovascular treatment (carotid artery stenting)
Trial: 18241759
Drug: Surgical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical treatment (carotid endarterectomy)
Trial: 12491829
Drug: Total parenteral
RxNorm normalized name: TPN - total parenteral nutrition
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total parenteral nutrition plus enteral feeding (TPN + EF)
Trial: 2651586
Drug: Surgical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical treatment in semicomatose/stuporous patients
Trial: 2651586
Drug: Conservative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conservative treatment in semicomatose/stuporous patients
Trial: 328033
Drug: Glafenin 200
RxNorm normalized name: Glafenine
DrugBank: Glafenine (DB08963)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glafenin 200 mg three times daily
Trial: 27825007
Drug: Standard 3-weekly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard 3-weekly chemotherapy
Trial: 23505993
Drug: Transdiagnostic cognitive-behavioral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdiagnostic cognitive-behavioral group therapy for anxiety
Trial: 15449262
Drug: Mechanical bowel
RxNorm normalized name: ascorbic acid
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mechanical bowel preparation with polyethylene glycol (PEG)
Trial: 15449262
Drug: Other bowel
RxNorm normalized name: Ether
DrugBank: Diethyl ether (DB13598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Other bowel preparations
Trial: 9143391
Drug: Recombinant human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Recombinant human interleukin-1 alpha (rhuIL-1 alpha) at doses of 0.1-10 micrograms/m2 for 4 days by subcutaneous injection before ICF chemotherapy
Trial: 9143391
Drug: Recombinant human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Recombinant human interleukin-1 alpha (rhuIL-1 alpha) administered after ICE chemotherapy
Trial: 9143391
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group receiving standard chemotherapy without rhuIL-1 alpha
Trial: 11823896
Drug: Chromium treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chromium treatment
Trial: 22031621
Drug: BMS‐690514, 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BMS‐690514, 200 mg after a high‐fat meal (951 kcal, 52% fat)
Trial: 22031621
Drug: BMS‐690514, 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BMS‐690514, 200 mg after a light meal (336 kcal, 75% carbohydrate)
Trial: 22031621
Drug: BMS‐690514, 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BMS‐690514, 200 mg while fasting
Trial: 20533105
Drug: Intensive sucralfate
RxNorm normalized name: Sucralfate
DrugBank: Sucralfate (DB00364)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive sucralfate therapy plus conventional therapy
Trial: 18466925
Drug: Buspirone (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buspirone (15 mg/day)
Trial: 18466925
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment (Estrogen 0.625 mg/d plus buspirone)
Trial: 12142810
Drug: Oral midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral midazolam (0.5 mg/kg, maximum dose of 20 mg) with IV meperidine (2 mg/kg, maximum dose of 100 mg)
Trial: 12142810
Drug: Oral diazepam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral diazepam (0.3 mg/kg, maximum dose of 10 mg) with IV meperidine (2 mg/kg, maximum dose of 100 mg)
Trial: 9927110
Drug: Epoetin alfa
RxNorm normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Epoetin alfa (weekly doses subcutaneously on Days -21, -14, -7, and day of surgery)
Trial: 8667039
Drug: Cefodizime 1
RxNorm normalized name: cefodizime
DrugBank: Cefodizime (DB13470)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefodizime 1 g i.m. qD (Group A)
Trial: 8667039
Drug: Cefodizime 1
RxNorm normalized name: cefodizime
DrugBank: Cefodizime (DB13470)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefodizime 1 g i.m. BID (Group B)
Trial: 8667039
Drug: Ceftriaxone 1
RxNorm normalized name: ceftriaxone 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftriaxone 1 g i.m. qD (Group C)
Trial: 2201431
Drug: Doxorubicin (70
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxorubicin (70 mg/m2 intravenously)
Trial: 2201431
Drug: Doxorubicin (70
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxorubicin (70 mg/m2 intravenously) and Vindesine (3 mg/m2 intravenously)
Trial: 28002882
Drug: LC28-0126 (0.3,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LC28-0126 (0.3, 1, 3, 10, 25, 50, 100, or 200 mg)
Trial: 28002882
Drug: LC28-0126 (0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LC28-0126 (0.3 to 200 mg)
Trial: 26032952
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose (1.5 mg NES/0.5 mg E2)
Trial: 26032952
Drug: Medium dose
RxNorm normalized name: TRIGLYCERIDES,MEDIUM CHAIN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medium dose (3.0 mg NES/1.0 mg E2)
Trial: 26032952
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose (4.5 mg NES/1.5 mg E2)
Trial: 23602417
Drug: Traditional Chinese
RxNorm normalized name: BORNEOL 1 g in 6.5 g / MINT 1 g in 6.5 g / ANGELICA DAHURICA ROOT 0.5 g in 6.5 g TOPICAL POWDER [Traditional Chinese Medicine Health Card and TCM Epidemic Prevention Card]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional Chinese Medicine (TCM) with standard rehabilitation
Trial: 11368131
Drug: Mifepristone 600
RxNorm normalized name: Mifepristone 600 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mifepristone 600 mg followed by misoprostol 400 microg 6-8 hours later (Group 1)
Trial: 11368131
Drug: Mifepristone 600
RxNorm normalized name: Mifepristone 600 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mifepristone 600 mg followed by misoprostol 400 microg 48 hours later (Group 2)
Trial: 1360776
Drug: 0.88 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.88 mg/kg oxatomide
Trial: 1360776
Drug: 1.5 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 mg/kg oxatomide
Trial: 6400576
Drug: Topical 1%
RxNorm normalized name: fluoride topical 1% topical gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 1% prednisolone acetate
Trial: 6400576
Drug: Steroid treated
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Steroid treated group (intervention)
Trial: 17896781
Drug: Local breast
RxNorm normalized name: chicken breast preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local breast irradiation and adjuvant therapy
Trial: 16116154
Drug: Intensive alkylator-based
RxNorm normalized name: petroleum alkylate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive alkylator-based induction chemotherapy with or without autologous bone marrow transplantation (ABMT) with or without 13 cis-retinoic acid.
Trial: 12169044
Drug: Desloratadine 7.5mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Desloratadine 7.5mg daily with erythromycin 500mg every 8 hours for 10 days
Trial: 12169044
Drug: Desloratadine 7.5mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Desloratadine 7.5mg daily with erythromycin
Trial: 12169044
Drug: Desloratadine 7.5mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Desloratadine 7.5mg daily with placebo
Trial: 10575337
Drug: Inhaled glutathione
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled glutathione (600 mg)
Trial: 27170445
Drug: BAT 1200
RxNorm normalized name: ODEVIXIBAT 1200MCG CAP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BAT 1200 μg via DPI-D
Trial: 27170445
Drug: BAT 1200
RxNorm normalized name: ODEVIXIBAT 1200MCG CAP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BAT 1200 μg via DPI-E without a lactose-filled second strip
Trial: 27170445
Drug: BAT 1200
RxNorm normalized name: ODEVIXIBAT 1200MCG CAP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BAT 1200 μg via DPI-E with a lactose-filled second strip
Trial: 27170445
Drug: BAT/FF 1200/300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BAT/FF 1200/300 μg via DPI-E
Trial: 27170445
Drug: FF 300
RxNorm normalized name: Gonal F RFF 300 UNT per 0.5 ML Pen Injector
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FF 300 μg via DPI-E with a lactose-filled second strip
Trial: 27170445
Drug: BAT/FF 900/300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BAT/FF 900/300 μg via DPI-E
Trial: 24526257
Drug: Prednisolone (2.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisolone (2.0 mg/kg/d)
Trial: 15556964
Drug: Epidural diamorphine
RxNorm normalized name: Diamorphine
DrugBank: Diamorphine (DB01452)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural diamorphine 3 mg (high-volume, low-concentration solution)
Trial: 15556964
Drug: Epidural diamorphine
RxNorm normalized name: Diamorphine
DrugBank: Diamorphine (DB01452)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural diamorphine 3 mg (low-volume, high-concentration solution)
Trial: 10566877
Drug: Phytosterol ester-enriched
RxNorm normalized name: phytosterol esters
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phytosterol ester-enriched margarine (40 g containing 8.6 g vegetable oil phytosterol)
Trial: 10654588
Drug: Control margarine
RxNorm normalized name: MARGARINE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control margarine (40 g)
Trial: 6881974
Drug: Levamisole group
RxNorm normalized name: Levamisole
DrugBank: Levamisole (DB00848)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Levamisole group (three-drug regimen: 5-FU, Adriamycin, and Levamisole)
Trial: 6881974
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (two-drug regimen: 5-FU and Adriamycin)
Trial: 31439467
Drug: Total Body
RxNorm normalized name: Total Body Massager Item
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total Body Weight (TBW) dosing, 1.22 mL/kg
Trial: 31439467
Drug: Lean Body
RxNorm normalized name: Cleanser Topical application Soap [NIVEA MEN ACTIVE CLEAN BODY WASH]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lean Body Weight (LBW) dosing, 1.66 mL/kg for women and 1.52 mL/kg for men
Trial: 31439467
Drug: TBW dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TBW dosing
Trial: 31439467
Drug: LBW dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LBW dosing
Trial: 31439467
Drug: TBW and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TBW and LBW dosing